Tamara Rordorf
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Digklia A, Kollár A, Felber Dietrich D, Kronig M, Britschgi C, Rordorf T, Jörger M, Krasniqi F, Metaxas Y, Colombo I, Ribi K, Rothermundt C. SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. Eur J Cancer 2023; 197:113470.
Dec 9, 2023SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Dec 9, 2023Eur J Cancer 2023; 197:113470
Digklia Antonia, Kollár Attila, Felber Dietrich Denise, Kronig M N, Britschgi Christian, Rordorf Tamara, Jörger Markus, Krasniqi Fatime, Metaxas Yannis, Colombo Ilaria, Ribi Karin, Rothermundt Christian
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Harrington K, Burtness B, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Lin J, Gumuscu B, Swaby R, Rischin D. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol 2022:JCO2102508.
Oct 11, 2022Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Oct 11, 2022J Clin Oncol 2022:JCO2102508
Harrington Kevin J, Burtness Barbara, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Brana Irene, Basté Neus, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Wan Ishak Wan Zamaniah, Lin Jianxin, Gumuscu Burak, Swaby Ramona F, Rischin Danny
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Rischin D, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Hong R, Mendoza R, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncol 2022; 128:105815.
Apr 2, 2022Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Apr 2, 2022Oral Oncol 2022; 128:105815
Rischin Danny, Harrington Kevin J, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Brana Irene, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Ishak Wan Zamaniah Wan, Hong Ruey-Long, Mendoza René Gonzalez, Jia Liyi, Chirovsky Diana, Norquist Josephine, Jin Fan, Burtness Barbara
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Ge J, Swaby R, Gumuscu B, Harrington K. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol 2022; 40:2321-2332.
Mar 25, 2022Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
Mar 25, 2022J Clin Oncol 2022; 40:2321-2332
Burtness Barbara, Rischin Danny, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Brana Irene, Basté Neus, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Wan Ishak Wan Zamaniah, Ge Joy, Swaby Ramona F, Gumuscu Burak, Harrington Kevin J
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Gillison M, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Jayaprakash V, Weibel L, Ferris R. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Oncologist 2022; 27:e194-e198.
Mar 4, 2022Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Mar 4, 2022Oncologist 2022; 27:e194-e198
Gillison Maura L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Iglesias Docampo Lara Carmen, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Jayaprakash Vijayvel, Weibel Lisa, Ferris Robert L
SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets.
Freiberger S, Brada M, Fritz C, Höller S, Vogetseder A, Horcic M, Bihl M, Michal M, Lanzer M, Wartenberg M, Borner U, Bode P, Broglie M, Rordorf T, Morand G, Rupp N. SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. Neoplasia 2021; 23:473-487.
Apr 18, 2021SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets.
Apr 18, 2021Neoplasia 2021; 23:473-487
Freiberger Sandra N, Brada Muriel, Fritz Christine, Höller Sylvia, Vogetseder Alexander, Horcic Milo, Bihl Michel, Michal Michal, Lanzer Martin, Wartenberg Martin, Borner Urs, Bode Peter K, Broglie Martina A, Rordorf Tamara, Morand Grégoire B, Rupp Niels J
Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.
Riesterer O, Pruschy M, Bender S, Sharma A, Bogowicz M, Tanadini-Lang S, Stieb S, Bertogg K, Weber S, Ikenberg K, Huber G, Schmid S, Bredell M, Veit-Haibach P, Rordorf T, Held U, Glanzmann C, Studer G. Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. Radiother Oncol 2020; 150:62-69.
Jun 12, 2020Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.
Jun 12, 2020Radiother Oncol 2020; 150:62-69
Riesterer Oliver, Pruschy Martin, Bender Sabine, Sharma Ashish, Bogowicz Marta, Tanadini-Lang Stephanie, Stieb Sonja, Bertogg Kaja, Weber Sandra, Ikenberg Kristian, Huber Gerhard, Schmid Stephan, Bredell Marius, Veit-Haibach Patrick, Rordorf Tamara, Held Ulrike, Glanzmann Christoph, Studer Gabriela
IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes.
Satoh T, Mellett M, Meier-Schiesser B, Fenini G, Otsuka A, Beer H, Rordorf T, Maul J, Hafner J, Navarini A, Contassot E, French L. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest 2020; 130:1417-1430.
Mar 2, 2020IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes.
Mar 2, 2020J Clin Invest 2020; 130:1417-1430
Satoh Takashi K, Mellett Mark, Meier-Schiesser Barbara, Fenini Gabriele, Otsuka Atsushi, Beer Hans-Dietmar, Rordorf Tamara, Maul Julia-Tatjana, Hafner Jürg, Navarini Alexander A, Contassot Emmanuel, French Lars E
Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease.
Nordmann T, Messerli-Odermatt O, Meier L, Micaletto S, Coppetti T, Nägeli M, Kamarachev J, Kudura K, Freiberger S, Rordorf T, Mangana J, Braun R, Dummer R. Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease. Oncotarget 2019; 10:6647-6650.
Nov 19, 2019Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease.
Nov 19, 2019Oncotarget 2019; 10:6647-6650
Nordmann Thierry M, Messerli-Odermatt Olivia, Meier Larissa, Micaletto Sara, Coppetti Thomas, Nägeli Mirjam, Kamarachev Jivko, Kudura Ken, Freiberger Sandra N, Rordorf Tamara, Mangana Joanna, Braun Ralph, Dummer Reinhard
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Hong R, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng J, Jin F, Rischin D. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394:1915-1928.
Nov 1, 2019Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Nov 1, 2019Lancet 2019; 394:1915-1928
Burtness Barbara, Harrington Kevin J, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Basté Neus, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Wan Ishak Wan Zamaniah, Hong Ruey-Long, González Mendoza René, Roy Ananya, Zhang Yayan, Gumuscu Burak, Cheng Jonathan D, Jin Fan, Rischin Danny
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Gillison M, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris R. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist 2018; 23:1079-1082.
Jun 4, 2018CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Jun 4, 2018Oncologist 2018; 23:1079-1082
Gillison Maura L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Iglesias Docampo Lara Carmen, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Monga Manish, Lynch Mark, Li Li, Ferris Robert L
FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.
Schneider P, Eshmuminov D, Rordorf T, Vetter D, Veit-Haibach P, Weber A, Bauerfeind P, Samaras P, Lehmann K. FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC cancer 2018; 18:548.
May 9, 2018FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study.
May 9, 2018BMC cancer 2018; 18:548
Schneider Paul M, Eshmuminov Dilmurodjon, Rordorf Tamara, Vetter Diana, Veit-Haibach Patrick, Weber Achim, Bauerfeind Peter, Samaras Panagiotis, Lehmann Kuno
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison M. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018; 81:45-51.
Apr 17, 2018Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Apr 17, 2018Oral Oncol 2018; 81:45-51
Ferris Robert L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Docampo Lara Carmen Iglesias, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Lynch Mark, Jayaprakash Vijayvel, Li Li, Gillison Maura L
Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy
Finazzi T, Rordorf T, Ikenberg K, Huber G, Guckenberger M, Garcia Schueler H. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. BMC cancer 2018; 18:395.
Apr 6, 2018Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy
Apr 6, 2018BMC cancer 2018; 18:395
Finazzi T, Rordorf Tamara, Ikenberg K, Huber Gerhard, Guckenberger M, Garcia Schueler H I
Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study.
Bredell M, Rordorf T, Kroiss S, Rücker M, Zweifel D, Rostetter C. Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study. J Oral Maxillofac Surg 2017; 76:775-784.
Sep 21, 2017Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study.
Sep 21, 2017J Oral Maxillofac Surg 2017; 76:775-784
Bredell Marius, Rordorf Tamara, Kroiss Sabine, Rücker Martin, Zweifel Daniel Fritz, Rostetter Claudio
Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel.
Rostetter C, Rordorf T, Essig H, Zweifel D, Schumann P, Rücker M, Bredell M. Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel. Swiss Dent J 2017; 127:520-521.
Jan 1, 2017Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel.
Jan 1, 2017Swiss Dent J 2017; 127:520-521
Rostetter Claudio, Rordorf Tamara, Essig Harald, Zweifel Daniel F, Schumann Paul, Rücker Martin, Bredell Marius
Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue.
Ernst J, Ikenberg K, Apel B, Schumann D, Huber G, Studer G, Rordorf T, Riesterer O, Rössle M, Korol D, Bredell M. Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue. Oncotarget 2016; 7:76151-76158.
Nov 15, 2016Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue.
Nov 15, 2016Oncotarget 2016; 7:76151-76158
Ernst Jutta, Ikenberg Kristian, Apel Barbara, Schumann Desiree M, Huber Gerhard, Studer Gabriela, Rordorf Tamara, Riesterer Oliver, Rössle Matthias, Korol Dimitri, Bredell Marius
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Rochlitz C, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Borner M, Bärtschi D, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na K. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. BMC cancer 2016; 16:780.
Oct 10, 2016SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Oct 10, 2016BMC cancer 2016; 16:780
Rochlitz Christoph, Rordorf Tamara, Rauch Daniel, Müller Andreas, Ruhstaller Thomas, Vetter Marcus, Trojan Andreas, Hasler-Strub Ursula, Cathomas Richard, Winterhalder Ralph, Borner Markus, Bärtschi Daniela, Bigler Martin, von Moos Roger, Bernhard Jürg, Matter-Walstra Klazien, Wicki Andreas, Zaman Khalil, Anchisi Sandro, Küng Marc, Na Kyung-Jae
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese W, Kopit J, Shaw J, Gillison M. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375:1856-1867.
Oct 8, 2016Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Oct 8, 2016N Engl J Med 2016; 375:1856-1867
Ferris Robert L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Iglesias Docampo Lara Carmen, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Monga Manish, Lynch Mark, Geese William J, Kopit Justin, Shaw James W, Gillison Maura L
IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80.
Brown M, Glanzmann C, Huber G, Bredell M, Rordorf T, Studer G. IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80. Strahlenther Onkol 2016; 192:526-36.
Jun 15, 2016IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80.
Jun 15, 2016Strahlenther Onkol 2016; 192:526-36
Brown Michelle L, Glanzmann Christoph, Huber Gerhard, Bredell Marius, Rordorf Tamara, Studer Gabriela